Back to search results

SNAPS Breast Cancer Patient Study

This observational study is looking at a special blood test called a proprietary immunogenomic signature to see if it can identify breast cancer in women. Researchers believe that analyzing specific immune cells (CD14 and CD2 cells) in your blood might show unique patterns related to breast cancer. You may be able to join if you are over 18, have been diagnosed with stage I-IV breast cancer but haven't started treatment yet, or are having a screening mammogram. You cannot join if you've had a different type of cancer in the last three years (unless it was non-melanoma skin cancer). The main goal is to see how well this blood test works after 12 months.

Study design
This is an observational study with a planned enrollment of 500 women. It is not specified if it's randomized or blinded.
What's involved
You would have a blood test. The record does not specify other procedures or the duration of your participation beyond the 12-month primary endpoint.
Compensation
Not stated in the trial record.
Follow-up
The primary aim is measured at 12 months, suggesting a follow-up period of at least 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05370300

SNAPS Breast Cancer Patient Study Breast Cancer Patients

Not Yet Recruiting
Not specifiedAges 18+Observational
Immunis.AI
~500 participants
Updated 2024-03-06 on ClinicalTrials.gov
What's tested:Blood test

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Aim
Measured over 12 months

Conditions

Breast Cancer
Breast Cancer Female

Explore related trials

Breast CarcinomaERBB2 GeneHR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Kirk Wojno, MD · PRINCIPAL_INVESTIGATOR · Immunis.AI

Who to contact

Amanda Nash
[email protected]
855-855-6484
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients \> 18 yrs of age.
Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy.
Patients undergoing screening mammograms for breast cancer.

Exclusion

Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer).
Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer.
Any biopsy which resulted in the entire tumor tissue being removed.
History of previous breast cancer.
Patients unable to provide informed consent.
Patients with an abnormal screening mammogram.
Patients whose hormone receptor and/or HER2 status are not available.

What this trial measures

  • Primary Aim12 months

    To determine if differential gene expression between peripheral blood phagocytic and non-phagocytic immune cells can distinguish breast cancer patients from cancer-negative controls.